Q3 2017 EPS Estimates for TESARO, Inc. Boosted by Leerink Swann (TSRO)

TESARO, Inc. (NASDAQ:TSRO) – Stock analysts at Leerink Swann increased their Q3 2017 earnings estimates for TESARO in a research report issued to clients and investors on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the biopharmaceutical company will post earnings per share of ($0.56) for the quarter, up from their previous estimate of ($2.01). Leerink Swann currently has a “Market Perform” rating and a $143.00 target price on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2017 earnings at ($2.40) EPS, FY2017 earnings at ($8.32) EPS, FY2018 earnings at ($4.29) EPS, FY2019 earnings at ($0.24) EPS, FY2020 earnings at $3.62 EPS and FY2021 earnings at $5.36 EPS.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same period last year, the firm posted ($1.28) EPS. TESARO’s revenue was down 17.6% on a year-over-year basis.

WARNING: This news story was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/08/13/q3-2017-eps-estimates-for-tesaro-inc-boosted-by-leerink-swann-tsro.html.

Other equities analysts also recently issued reports about the stock. Credit Suisse Group set a $198.00 target price on shares of TESARO and gave the stock a “buy” rating in a research report on Monday, June 5th. Citigroup Inc. reissued a “buy” rating and set a $216.00 target price (down from $232.00) on shares of TESARO in a research report on Saturday, April 22nd. Cann reissued a “buy” rating and set a $199.00 target price on shares of TESARO in a research report on Monday, June 5th. Oppenheimer Holdings, Inc. set a $199.00 target price on shares of TESARO and gave the stock a “buy” rating in a research report on Sunday, June 4th. Finally, Bank of America Corporation reissued a “buy” rating and set a $154.00 target price on shares of TESARO in a research report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $176.35.

Shares of TESARO (NASDAQ TSRO) opened at 111.85 on Friday. The stock’s market cap is $6.06 billion. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The stock has a 50 day moving average price of $130.46 and a 200 day moving average price of $149.15.

Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in TESARO by 0.4% in the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock worth $1,237,718,000 after buying an additional 32,918 shares during the period. BlackRock Inc. increased its stake in TESARO by 5.7% in the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares during the period. Vanguard Group Inc. increased its stake in TESARO by 2.1% in the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after buying an additional 62,104 shares during the period. State Street Corp increased its stake in TESARO by 0.4% in the first quarter. State Street Corp now owns 991,856 shares of the biopharmaceutical company’s stock worth $152,617,000 after buying an additional 3,784 shares during the period. Finally, BB Biotech AG increased its stake in TESARO by 6.5% in the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after buying an additional 53,408 shares during the period.

In related news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now directly owns 5,396 shares of the company’s stock, valued at $748,155.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 40.50% of the stock is owned by company insiders.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply